TechMARK movers: Oxford Biomedica award

22nd Sep 2010 12:33

Oxford Biomedica is higher after its TroVax vaccine was chosen as one of the 10 oncology projects to watch by Windhover Information and the publishers of In Vivo and Start Up industry publications.TroVax is designed to stimulate the immune system to destroy cancer cells. A phase II study for the treatment of prostate cancer is planned.Some shareholders are taking profits after the sharp rise in the share price of Biocompatibles International following yesterday's announcement of a bid approach. FTSE TechMARK - RisersOxford Instruments (OXIG) 465.00p +5.86%Oxford Biomedica (OXB) 9.60p +4.23%Network Technology (NTY) 1,875.00p +4.00%Renovo Group (RNVO) 27.50p +3.77%Alterian (ALN) 188.00p +3.58%E2V Technologies (E2V) 75.00p +3.45%ProStrakan (PSK) 55.75p +3.24%XP Power (XPP) 882.00p +2.44%Asterand (ATD) 10.75p +2.33%FTSE TechMARK - FallersPace (PIC) 189.50p -4.53%Autonomy Corporation (AU.) 1,764.00p -3.55%Puricore (PURI) 60.50p -3.20%Consort Medical (CSRT) 438.00p -2.67%Ark Therapeutics (AKT) 4.75p -2.66%Triad Group (TRD) 19.50p -2.56%DRS Data (DRS) 21.25p -2.35%Biocompatibles International (BII) 345.00p -2.27%Phytopharm (PYM) 8.68p -1.36%Anite Group (AIE) 49.50p -1.00%